Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results
Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Christopher T. Chen(Palo Alto University)
Cited by 7
Related Papers
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
|Nature Medicine|2023|372
Phase 2 study of pembrolizumab in patients with advanced rare cancers
|Journal for ImmunoTherapy of Cancer|2020|130